217 related articles for article (PubMed ID: 11751526)
1. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Hara I; Kamidono S; Gleave ME
Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
[TBL] [Abstract][Full Text] [Related]
2. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
5. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.
Miyake H; Eto H; Hara I; So A; Li D; Gleave ME
J Urol; 2004 Jun; 171(6 Pt 1):2477-81. PubMed ID: 15126879
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer.
Miyake H; Hanada N; Nakamura H; Kagawa S; Fujiwara T; Hara I; Eto H; Gohji K; Arakawa S; Kamidono S; Saya H
Oncogene; 1998 Feb; 16(7):933-43. PubMed ID: 9484785
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
9. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential.
Miyake H; Hara I; Yamanaka K; Muramaki M; Gleave M; Eto H
Oncol Rep; 2005 Feb; 13(2):341-5. PubMed ID: 15643522
[TBL] [Abstract][Full Text] [Related]
10. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 Jan; 60(1):170-6. PubMed ID: 10646870
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells.
Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
Br J Cancer; 1999 Apr; 79(11-12):1651-6. PubMed ID: 10206273
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Yamanaka K; Gleave ME; Hara I; Muramaki M; Miyake H
Mol Cancer Ther; 2005 Feb; 4(2):187-95. PubMed ID: 15713890
[TBL] [Abstract][Full Text] [Related]
15. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.
Chen T; Turner J; McCarthy S; Scaltriti M; Bettuzzi S; Yeatman TJ
Cancer Res; 2004 Oct; 64(20):7412-9. PubMed ID: 15492264
[TBL] [Abstract][Full Text] [Related]
16. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
17. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
19. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells.
Gao XD; Chen YR
Chin Med J (Engl); 2007 May; 120(9):755-60. PubMed ID: 17531113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
